Antje Wick
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
03.05.2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
03.05.2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
22.11.2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
22.11.2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje